Literature DB >> 25003192

Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

Yan Lu, Xing Liu, Yang Jiao, Xuelian Xiong, E Wang, Xiaolin Wang, Zhijian Zhang, Huijie Zhang, Lingling Pan, Youfei Guan, Dongsheng Cai, Guang Ning, Xiaoying Li.   

Abstract

Hepatosteatosis is characterized by an aberrant accumulation of triglycerides in the liver; however, the factors that drive obesity-induced fatty liver remain largely unknown. Here, we demonstrated that the secreted cell adhesion protein periostin is markedly upregulated in livers of obese rodents and humans. Notably, overexpression of periostin in the livers of WT mice promoted hepatic steatosis and hypertriglyceridemia. Conversely, both genetic ablation of periostin and administration of a periostin-neutralizing antibody dramatically improved hepatosteatosis and hypertriglyceridemia in obese mice. Overexpression of periostin resulted in reduced expression of peroxisome proliferator-activated receptor α (PPARα), a master regulator of fatty acid oxidation, and activation of the JNK signaling pathway. In mouse primary hepatocytes, inhibition of α6β4 integrin prevented activation of JNK and suppression of PPARα in response to periostin. Periostin-dependent activation of JNK resulted in activation of c-Jun, which prevented RORα binding and transactional activation at the Ppara promoter. Together, these results identify a periostin-dependent pathway that mediates obesity-induced hepatosteatosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25003192      PMCID: PMC4109546          DOI: 10.1172/JCI74438

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  72 in total

1.  Glucose-mediated repression of menin promotes pancreatic β-cell proliferation.

Authors:  Hongli Zhang; Wenyi Li; Qidi Wang; Xiao Wang; Fengying Li; Cuiping Zhang; Ling Wu; Hongmei Long; Yun Liu; Xiaoying Li; Min Luo; Guo Li; Guang Ning
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  Production of monoclonal antibodies.

Authors:  Wayne M Yokoyama; Michelle Christensen; Gary Dos Santos; Diane Miller; Jason Ho; Tao Wu; Michael Dziegelewski; Francisca A Neethling
Journal:  Curr Protoc Immunol       Date:  2013-10-01

Review 3.  JNK regulation of hepatic manifestations of the metabolic syndrome.

Authors:  Mark J Czaja
Journal:  Trends Endocrinol Metab       Date:  2010-10-01       Impact factor: 12.015

4.  Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation.

Authors:  Kim Ravnskjaer; Michael Boergesen; Louise T Dalgaard; Susanne Mandrup
Journal:  J Mol Endocrinol       Date:  2006-04       Impact factor: 5.098

5.  Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes.

Authors:  David M Flavell; Helen Ireland; Jeffrey W Stephens; Emma Hawe; Jay Acharya; Hugh Mather; Steven J Hurel; Steve E Humphries
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

6.  A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.

Authors:  Shaohua Chen; Youming Li; Shengjie Li; Chaohui Yu
Journal:  J Gastroenterol Hepatol       Date:  2008-09       Impact factor: 4.029

Review 7.  The role of hepatokines in metabolism.

Authors:  Norbert Stefan; Hans-Ulrich Häring
Journal:  Nat Rev Endocrinol       Date:  2013-01-22       Impact factor: 43.330

8.  Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway.

Authors:  Shideng Bao; Gaoliang Ouyang; Xuefang Bai; Zhi Huang; Chaoyu Ma; Ming Liu; Rong Shao; Ryan M Anderson; Jeremy N Rich; Xiao-Fan Wang
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

Review 9.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress.

Authors:  Stanley M H Chan; Ruo-Qiong Sun; Xiao-Yi Zeng; Zi-Heng Choong; Hao Wang; Matthew J Watt; Ji-Ming Ye
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

View more
  45 in total

1.  Periostin on the road to nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  Endocrine       Date:  2015-11-19       Impact factor: 3.633

2.  Bioinformatics Analysis of Key Differentially Expressed Genes in Nonalcoholic Fatty Liver Disease Mice Models.

Authors:  Chao Hou; Wenwen Feng; Shan Wei; Yulin Wang; Xiaoyi Xu; Jin Wei; Ziliang Ma; Yongsheng Du; Jialin Guo; Yu He; Fanyun Kong; Renxian Tang; Kuiyang Zheng
Journal:  Gene Expr       Date:  2018-08-22

3.  Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.

Authors:  Terry D Hinds; Peter A Hosick; Shujuan Chen; Robert H Tukey; Michael W Hankins; Andrea Nestor-Kalinoski; David E Stec
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-01-17       Impact factor: 4.310

4.  Fibrate pharmacogenomics: expanding past the genome.

Authors:  John S House; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2020-03-17       Impact factor: 2.533

5.  Epidermal growth factor receptor restoration rescues the fatty liver regeneration in mice.

Authors:  Teresa A Zimmers; Xiaoling Jin; Zongxiu Zhang; Yanlin Jiang; Leonidas G Koniaris
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-06-27       Impact factor: 4.310

6.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

7.  Relationships among injury, fibrosis, and time in human kidney transplants.

Authors:  Jeffery M Venner; Konrad S Famulski; Jeff Reeve; Jessica Chang; Philip F Halloran
Journal:  JCI Insight       Date:  2016-01-21

8.  Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.

Authors:  Jin-Zhou Zhu; Hua-Tuo Zhu; Yi-Ning Dai; Chun-Xiao Li; Zhi-Yun Fang; De-Jian Zhao; Xing-Yong Wan; Yu-Ming Wang; Fang Wang; Chao-Hui Yu; You-Ming Li
Journal:  Endocrine       Date:  2015-09-11       Impact factor: 3.633

9.  Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via αv integrin interaction.

Authors:  Akiko Sugiyama; Keishi Kanno; Norihisa Nishimichi; Shoichiro Ohta; Junya Ono; Simon J Conway; Kenji Izuhara; Yasuyuki Yokosaki; Susumu Tazuma
Journal:  J Gastroenterol       Date:  2016-04-04       Impact factor: 7.527

10.  Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor.

Authors:  Yan Lu; E Wang; Ying Chen; Bing Zhou; Jiejie Zhao; Liping Xiang; Yiling Qian; Jingjing Jiang; Lin Zhao; Xuelian Xiong; Zhiqiang Lu; Duojiao Wu; Bin Liu; Jing Yan; Rong Zhang; Huijie Zhang; Cheng Hu; Xiaoying Li
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.